NCT02456844 - Study to Investigate the Effect of BMS-986142 on the Pharmacokinetics (PK) of Methotrexate and Probe Substrate Cocktail in Healthy Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions

Rheumatoid Arthritis

Interventions

DRUG

Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142

"1. Montelukast 10-mg tablet: On Days 1 and 8,Single oral dose~2. Flurbiprofen 50-mg tablet: On Days 1 and 8,Single oral dose~3. Midazolam syrup 2.5 mL × 2 mg/mL (5 mg): On Days 1 and 8,Single oral dose~4. Digoxin (Lanoxin®) 0.25 mg tablet: On Days 1 and 8,Single oral dose~5. Pravastatin 40-mg tablet: On Days 1 and 8,Single oral dose~6. BMS-986142: On Days 6 through 12."

DRUG

Methotrexate, Leucovorin and BMS-986142

"1. Methotrexate (MTX) single oral dose of 3 × 2.5-mg tablet (Days 1 and 8)~2. Leucovorin single oral dose of 15-mg tablet (Days 2 and 9; 24 hours after MTX administration)~3. BMS-986142 on Days 6 through 10."